Medindia

X

CareFusion Alaris(R) Infusion System Recognized as One of the 'Best All-Around' Pumps In KLAS Report

Wednesday, April 21, 2010 General News J E 4
Advertisement


SAN DIEGO, April 20 A new report from KLAS, an independent health care vendor research firm, concluded the CareFusion (NYSE: CFN) Alaris® System is one of the "best all-around" infusion pump options for hospitals, with 99 percent of interviewed customers stating they would repeat their decision and purchase the Alaris System again.

For the report titled, Smart Pumps: Avoiding Buyer's Remorse*, KLAS spoke to 348 providers, including nurses, pharmacists and biomedical technologists, about their experiences with smart infusion pumps. The Alaris System was commended for its strong wireless capabilities, ease of use and scalability.

The report also highlighted the product's ability to satisfy clinicians and other hospital stakeholders by concluding, "purchasing infusion pumps is a multi-stakeholder decision, and Alaris has shown its ability to satisfy nearly every stakeholder at almost every type of facility."

"Recognition from KLAS is noteworthy because their report is based on direct feedback from customers," said David Schlotterbeck, chairman and CEO of CareFusion. "As a company dedicated to helping improve patient safety and clinical workflow in hospitals, we are pleased to see clinicians and hospital staff value their investment with us."

In the report, the CareFusion Alaris® Syringe module was named the top syringe product, and the Alaris® large volume pump (LVP) and PCA products were named second in their respective categories.

The Alaris business has the largest installed base of infusion customers in the U.S. The Alaris System is a modular multi-modality IV medication safety system that protects all types of infusions, large volume, patient-controlled analgesia and syringe. The system also includes a bar-coding module and integrated respiratory monitoring.

* Smart Pumps: Avoiding Buyer's Remorse, March 2010. KLAS Confidential Information. © 2010 KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com.

About KLAS

KLAS is a research firm specializing in monitoring and reporting the performance of health care vendors. KLAS' mission is to improve delivery, by independently measuring vendor performance for the benefit of our healthcare provider partners, consultants, investors and vendors. Working together with executives from more than 4,500 hospitals and over 2,500 clinics, KLAS delivers timely reports, trends and statistics, which provide a solid overview of vendor performance in the industry. KLAS measures the performance of software, professional services and medical equipment vendors. For more information, go to www.KLASresearch.com, email marketing@KLASresearch.com or call 1-800-920-4109 to speak with a KLAS representative.

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife(TM) and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined(TM) services for infection surveillance, NeuroCare neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at www.carefusion.com.

SOURCE CareFusion Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Dogs Will Savor the Flavor of New Wellness(R) Stew...
S
Talecris Biotherapeutics Announces Results of Annu...